Yes, generic Ozempic is real, and it’s sold in Canada. On April 28, 2026, Health Canada approved the first generic semaglutide (from Dr. Reddy’s), which made Canada the first G7 country to do so. Apotex followed on May 1, and generic pens reached Canadian pharmacies the week of May 19. Then on June 29, Health Canada approved Sevmia, Apotex’s generic version of Wegovy for weight management. Aspen (July) and Sandoz (September) have been approved since.
Canada got generics years before the US because Novo Nordisk let its Canadian semaglutide patent lapse over an unpaid maintenance fee in 2019. In a June 2026 phone survey of three Ontario pharmacy chains, generic semaglutide cost about $89–$104 a month cash, against roughly $258–$282 for brand Ozempic. You still need a prescription, and coverage depends on your provincial or private plan.
Why Canada got generic semaglutide first
Big-brand drugs usually stay protected for years after their key patent expires, because drug makers stack patents, extensions and data protection on top of each other. Semaglutide in Canada went differently.
The $450 patent fee story
Canadian patents stay alive only if the owner pays a yearly maintenance fee. According to UK patent firm Reddie & Grose, Novo Nordisk missed a C$250 maintenance fee in 2019 on its core Canadian semaglutide patent (CA 2601784). Novo was given an extra year to pay, which with the late fee came to C$450, and it didn’t pay. The Canadian Intellectual Property Office is blunt about what happens next: “once a patent has lapsed it cannot be revived.”
That missed fee had a knock-on effect. The patent was due to run until 2026, and a linked certificate of supplementary protection could have pushed exclusivity to 2028. Once the patent lapsed, the certificate stopped working too.
Mistake or strategy?
Nobody outside Novo knows. Novo has said only that “all intellectual property decisions are carefully considered at a global level,” and its Canadian president declined to give details, citing confidentiality. Some commentators think the lapse was on purpose: a lapsed patent takes the drug out of reach of Canada’s Patented Medicine Prices Review Board, the federal price regulator, and that may have been worth more to Novo than two extra years of exclusivity. The Canadian Press reported that Canada is the only country where Novo let the semaglutide patent expire.
Why generics didn’t arrive in 2020
The patent was gone, but Canada’s separate data protection rule still blocked copies. That protection ended on January 4, 2026. By late December 2025, Health Canada had already received nine generic semaglutide submissions, including ones from Sandoz, Apotex, Teva, Taro and Aspen. In January, experts told Canadians not to expect a product that month, and that turned out to be right: the first approval came almost four months later.
Which generics are approved, and when
Here is the timeline we could verify from Health Canada releases and company announcements, up to October 2026.
| Date | Company | Copy of | Approved for | Status |
|---|---|---|---|---|
| April 28, 2026 | Dr. Reddy’s (India) | Ozempic | Type 2 diabetes, adults | First generic semaglutide in the G7. Reached “select” pharmacies in May |
| May 1, 2026 | Apotex (Canada) | Ozempic | Type 2 diabetes, adults | Began shipping May 19, 2026 |
| June 29, 2026 | Apotex: Sevmia | Wegovy | Chronic weight management, ages 12+ | First generic Wegovy in Canada |
| July 20, 2026 | Aspen Pharmacare | Ozempic | Type 2 diabetes | Launch tied to ingredient supply |
| September 18, 2026 | Sandoz Canada | Ozempic | Type 2 diabetes, adults | “Preparing for a future commercial launch” |
When it approved Sevmia, Health Canada said six more generic semaglutide submissions were still under review, with decisions expected “in the coming weeks and months.” Aspen and Sandoz were approved after that. As of October 2026 we found no approval announcement for Teva or Taro, which were also on the applicant list.
Being approved doesn’t mean being on the shelf. In July 2026, Dr. Reddy’s said an impurity found in its active ingredient had halted production of new batches, and that its Canadian supply would be disrupted until at least late October. Aspen also buys its ingredient from Dr. Reddy’s. If your pharmacy is out of one brand of generic, ask whether another is in stock.
Prices: brand vs generic in 2026
This is probably the part you searched for. Canadian pharmacies don’t post drug prices online, so real numbers are hard to find. Here are the ones we could verify.
| Product | Monthly cash price | Source and date |
|---|---|---|
| Brand Ozempic | $258.19–$282.00 | Teletest phone check, Costco/Rexall/Shoppers (Ontario), June 9, 2026 |
| Generic semaglutide (Ozempic generic) | $88.88–$103.53 | Same survey, same chains, dispensing fee included |
| Brand Wegovy | $431.12–$492.80 | Teletest phone check, Ontario, June 9, 2026 |
| Felix (online platform) semaglutide | $150 | Launch price announced May 2026 (Canadian Press) |
| Sevmia (generic Wegovy) | Not published | We found no verified retail price |
Prices change with dose, pharmacy, province and dispensing fee, so treat these as a snapshot, not a quote. The survey covered only three Ontario chains. When Apotex launched, it said its generic would cost about one-third of brand Ozempic. Dr. Reddy’s would only call its price “competitive.”
Why prices should keep falling
Generic prices in Canada follow the pan-Canadian Pharmaceutical Alliance (pCPA) framework, which gets steeper as more generics enter the market. When two generics are on the market, they must be priced at least 50% below the brand, and companies can go lower. University of Toronto drug-policy researcher Mina Tadrous said in January that with several competitors, prices could drop to about 35% of the brand. Health Canada’s own line is that generics in Canada usually cost 45% to 90% less than the brand.
Novo’s response: a cheaper brand
Novo didn’t sit still. On May 26, 2026, it said it would cut what uninsured Canadians pay for brand Ozempic, “aligning their medication costs with generic alternatives.” The discount comes through the Novo Nordisk Savings Card at pharmacies outside Quebec, and applies automatically at Novo Nordisk Care Rx, run by Rexall. Novo didn’t publish the new price. If you prefer to stay on the brand, ask your pharmacist whether the card applies to you.
For how semaglutide compares with other weight-loss medicines on cost, see our guide to weight-loss injections in Canada.
Coverage: provincial plans and private insurance
Provincial drug plans
Coverage is decided province by province, and each plan moves on its own timeline. Ontario was early: its Ontario Drug Benefit formulary listed the Apotex and Dr. Reddy’s generic pens as interchangeable with Ozempic under Limited Use, effective June 30, 2026. Interchangeable means a pharmacist can dispense the generic in place of the brand.
The key limit is that public plans cover semaglutide for type 2 diabetes, not weight loss. A June 2026 check of provincial formularies found Ozempic covered only for type 2 diabetes in Ontario (Limited Use), British Columbia (Special Authority), Alberta (Special Authorization), Saskatchewan (Exception Drug Status), Manitoba (Part 1) and Quebec (listed). The same source found Wegovy not listed on Ontario’s plan. If you want semaglutide for weight management and you’re on a public plan, expect to pay cash.
Private insurance
Private insurers are adjusting too. Sun Life, for example, told advisors it will keep requiring prior authorization for Ozempic and its generics. It will apply generic substitution to Ozempic claims once pharmacists can substitute and supply is widely available, and members already approved for Ozempic can move to a generic without reapplying. Weight-management drugs like Sevmia fall under obesity coverage, which Sun Life treats as an optional add-on that employers choose whether to buy.
Ask your insurer three things:
- Is generic semaglutide covered, and does my plan require the generic over the brand?
- Is prior authorization needed, and for which diagnosis?
- Does my plan include an obesity or weight-management benefit (which would cover Wegovy or Sevmia)?
Prescription costs you pay yourself may also count toward the federal medical expense tax credit, so keep your receipts.
How to get generic semaglutide in Canada
Generic semaglutide is a prescription drug, just like Ozempic and Wegovy. A generic is cheaper, but it’s not over-the-counter. Here’s the realistic path:
- See a prescriber. That can be your family doctor, a nurse practitioner, a walk-in clinic or a licensed virtual-care service. They’ll check whether semaglutide suits you and which product fits your diagnosis.
- Know which product matches your diagnosis. The Ozempic generics are approved for type 2 diabetes in adults. Sevmia is the generic approved for chronic weight management. Using an Ozempic generic for weight loss would be off-label, the same as with brand Ozempic.
- Ask the pharmacist about substitution. The Neighbourhood Pharmacy Association of Canada says pharmacists can substitute the generic for brand Ozempic under existing provincial rules, unless your prescriber wrote “no substitution” or you have a clinical reason to need the brand.
- Compare prices. Cash prices differed by about $15 a month between three Ontario chains in June 2026. Online pharmacies and platforms such as Felix compete on price too.
- Check stock. Supply has been uneven, especially for Dr. Reddy’s product. Calling ahead saves a wasted trip.
How to start, adjust or stop treatment is a conversation for your doctor or pharmacist. This guide won’t cover it. If you’re already on brand Ozempic and want to switch, ask them how to make the change safely.
“Generic semaglutide” sold without a prescription, as powder in a vial, or by websites that skip the medical assessment is not a Health Canada–approved generic. The approved generics are prefilled pens dispensed by a licensed pharmacy. If a website offers it with no prescription, treat that as a red flag.
Ozempic vs Wegovy vs the generics
Ozempic and Wegovy contain the same molecule, semaglutide. They’re approved for different conditions and come as different pens and strengths. The generics copy one brand or the other, not both.
| Ozempic (brand) | Ozempic generics | Wegovy (brand) | Sevmia (generic Wegovy) | |
|---|---|---|---|---|
| Maker | Novo Nordisk | Dr. Reddy’s, Apotex, Aspen, Sandoz | Novo Nordisk | Apotex |
| Approved use in Canada | Type 2 diabetes | Type 2 diabetes, adults | Chronic weight management | Chronic weight management, ages 12+ |
| Form | Once-weekly prefilled pen | Once-weekly prefilled pen | Once-weekly prefilled pen | Once-weekly prefilled pen |
| Typical cash price (June 2026, Ontario) | ~$258–$282/month | ~$89–$104/month | ~$431–$493/month | Not published |
| Public plan coverage | T2D only, criteria vary | Listed as interchangeable in Ontario (T2D, Limited Use) | Generally not covered | Generally not covered (weight management) |
One practical point: an Ozempic generic substitutes for Ozempic, and Sevmia substitutes for Wegovy. A pharmacist can’t simply swap an Ozempic prescription for Sevmia, because they’re different products with different approvals. If you want the weight-management version, your prescription needs to say so.
For how semaglutide compares with tirzepatide and the newer triple agonists, see retatrutide vs tirzepatide vs semaglutide. On common side-effect worries, we have separate guides on hair loss on Ozempic and muscle loss on GLP-1 drugs.
Is the generic as good as the brand?
This is the most common worry, and the honest answer has two parts.
What Health Canada says
Brand semaglutide is made with a biological process. Most generic versions are made by chemical synthesis, so Health Canada calls them “complex synthetic products.” That makes these reviews harder than for a typical generic pill. Health Canada says the approved generics are “pharmaceutically equivalent to the brand name biologic drug.” It also says its review checks that any differences between products “do not affect the safety, efficacy, or quality of the drug.” The review wasn’t a rubber stamp: before Dr. Reddy’s was approved, Health Canada told both Dr. Reddy’s and Sandoz that their first applications did not yet meet requirements.
Health Canada also says it will keep monitoring the safety and effectiveness of all generic semaglutide products now on the market.
What doctors say
McMaster endocrinologist Dr. Hertzel Gerstein told Global News that Health Canada goes “through a very rigorous process.” He added that approval should reassure most people the generic will have a very similar, if not identical, effect. Vancouver endocrinologist Dr. Ehud Ur was more cautious: he said generics should “theoretically” match the brand, but some patients may respond less well and stay on the original.
The practical takeaway is that the generics passed the same standard of review Canada uses for every generic, plus extra scrutiny because the original is a biologic. If you switch and notice a change in how you feel or in your blood sugar, tell your prescriber. That’s worth doing with any medication change.
Can Americans buy generic semaglutide from Canada?
This gets searched a lot from south of the border, so here’s the plain answer. Generic semaglutide isn’t FDA-approved in the US, and pharmacist Scott Gavura wrote in March 2026 that US generics are “still several years away.” The Congressional Research Service puts the general rule simply: “Current law generally does not permit individuals to import or reimport prescription drugs for their own use.” The FDA sometimes allows a 90-day personal supply of an unapproved drug, but only under narrow conditions, one of which is that no effective treatment is available in the United States. Brand semaglutide is available in the US.
A Canadian pharmacy also needs a valid prescription to dispense, and Novo Nordisk has lobbied Ottawa to stop online pharmacies selling to people who aren’t Canadian residents. If you live in the US, talk to a US prescriber about your options. Don’t look for workarounds.
What’s next: pills and new drugs
Generic injectables are only the first change. Several other things are coming through Health Canada:
- Orforglipron (Foundayo). Lilly’s once-daily GLP-1 pill was FDA-approved for obesity in April 2026. Health Canada’s list of submissions under review shows orforglipron accepted for review in January 2026. Our orforglipron and Foundayo guide covers the trial data and timing.
- The Wegovy pill (oral semaglutide). It was approved in the US in December 2025. Novo said it had applied to Health Canada, and we found no Canadian approval as of October 2026.
- CagriSema. Health Canada’s review list shows a cagrilintide–semaglutide combination from Novo Nordisk accepted in March 2026.
- More generics. Sandoz and Aspen are approved but not yet widely launched, and other applicants are still waiting. More competitors should push the pCPA price tiers lower.
Tirzepatide (Mounjaro, Zepbound) is a different story. Lilly still holds its Canadian patent, so no generic tirzepatide is coming soon. For the newest drugs in development, see the next weight-loss drugs after Ozempic.
Generic Ozempic myths
“Myth: Generic semaglutide is the same as compounded semaglutide.”
No. A Health Canada–approved generic has been reviewed for safety, efficacy and quality, and comes from a licensed manufacturer. In the US, “compounded semaglutide” usually means a product mixed by a pharmacy without FDA approval. These are different things.
“Myth: Generic Ozempic doesn’t need a prescription.”
It does. Generic status changes the price, not whether you need a prescription.
“Myth: You can use generic Ozempic and Sevmia interchangeably.”
Not at the pharmacy counter. Each generic substitutes only for its own reference brand, and the two have different approved uses.
“Myth: Insurance now covers semaglutide for weight loss because it’s generic.”
Not automatically. Public plans still cover semaglutide for type 2 diabetes, and private plans still decide weight-management coverage plan by plan. A lower price may change those decisions over time, but it hasn’t changed them yet.
“Myth: Canada’s generic is a knockoff.”
Health Canada’s position is that the approved generics are pharmaceutically equivalent to the brand, and its review confirmed that any differences don’t affect safety, efficacy or quality.
For researchers
To be clear: TrueLabs does not sell semaglutide, generic or brand, and nothing on our shop is a substitute for a prescription medicine. If you’re a patient, the products above are what you want, through your doctor and pharmacist.
For laboratories studying incretin and amylin biology, TrueLabs supplies research-grade reagents for in vitro use only: TZ-2 (tirzepatide) from $73, RT3 (retatrutide) from $90, and Cagrilintide from $40. These are not drugs, are not for human or veterinary use, and are not the same as any approved product. Background reading: tirzepatide research in Canada and our cagrilintide research guide. To check identity and purity, see How to read a peptide COA and the COA library.
FAQ
Tap a question to reveal the answer.
Is generic Ozempic available in Canada?
Yes. Health Canada approved the first generic semaglutide (Dr. Reddy’s) on April 28, 2026, and Apotex’s on May 1, 2026. Apotex began shipping on May 19, 2026, and chains including Shoppers Drug Mart and Rexall began receiving stock over the following days. Aspen and Sandoz have also been approved since.
How much does generic semaglutide cost in Canada?
A June 2026 phone survey of three Ontario chains found generic semaglutide at about $88.88 to $103.53 a month cash, including the dispensing fee. Brand Ozempic was $258.19 to $282 at the same chains. Prices vary by dose, pharmacy and province, and should keep falling as more generics launch.
What is Sevmia?
Sevmia is Apotex’s generic version of Wegovy, approved by Health Canada on June 29, 2026. It is a once-weekly semaglutide injection for chronic weight management in people aged 12 and older, alongside diet and physical activity. It was the third generic semaglutide approved in Canada.
Why does Canada have generic semaglutide before the US?
Novo Nordisk did not pay a maintenance fee on its core Canadian semaglutide patent in 2019, so the patent lapsed and cannot be revived. Once Canada’s data protection period ended on January 4, 2026, generic makers could be approved. In the US, generics are still described as several years away.
Do I need a prescription for generic Ozempic?
Yes. Generic semaglutide is a prescription drug like the brand. You can get a prescription from a doctor, a nurse practitioner or a licensed virtual-care service, and then fill it at a pharmacy.
Is generic semaglutide as effective as Ozempic?
Health Canada says the approved generics are pharmaceutically equivalent to the brand, and that its review found differences between products don’t affect safety, efficacy or quality. Most doctors quoted in Canadian media expect the same results. If anything changes after you switch, tell your prescriber.
Will my provincial plan cover generic semaglutide?
For type 2 diabetes, often yes, under each province’s criteria. Ontario listed the Apotex and Dr. Reddy’s generics as interchangeable with Ozempic from June 30, 2026. Public plans generally don’t cover semaglutide for weight loss.
Can my pharmacist switch me from Ozempic to the generic?
Under existing provincial rules, pharmacists can substitute the generic for brand Ozempic unless your prescriber wrote no substitution or you have a clinical need for the brand. Your insurer may also require the generic. Ask your pharmacist and prescriber before any switch.
Can I buy generic semaglutide from Canada if I live in the US?
US law generally doesn’t allow individuals to import prescription drugs for their own use, and generic semaglutide isn’t FDA-approved. Canadian pharmacies also need a valid prescription to dispense. US residents should talk to a US prescriber.
Does TrueLabs sell semaglutide?
No. TrueLabs doesn’t sell semaglutide in any form. We supply research peptides such as TZ-2, RT3 and Cagrilintide strictly for in vitro laboratory research, not for human use.
Related reading
- Weight-loss injections in Canada
- Orforglipron (Foundayo): the GLP-1 pill and Canada
- The next weight-loss drugs after Ozempic
- Retatrutide vs tirzepatide vs semaglutide
- Peptide prices in Canada
- Hair loss on Ozempic
References
- Health Canada. Canada becomes the first G7 country to approve a generic version of semaglutide. News release, April 28, 2026. canada.ca
- Health Canada. Canada approves second generic semaglutide, the first G7 country to do so. News release, May 1, 2026. canada.ca
- Health Canada. Canada approves first generic semaglutide for weight loss. News release, June 29, 2026. canada.ca
- The Canadian Press. Companies can make generic Ozempic as of next week in Canada, but don’t expect to get it soon. BNN Bloomberg. January 2, 2026. BNN Bloomberg
- Reddie & Grose. A key Ozempic patent lapses in Canada – deliberate or a mistake? October 15, 2025. reddie.co.uk
- The Canadian Press. Generic semaglutide to hit Canadian pharmacies this week at a fraction of the cost of Ozempic. BNN Bloomberg. May 20, 2026. BNN Bloomberg
- Global News. Report on Novo Nordisk lowering brand Ozempic costs for uninsured Canadians. May 26, 2026. Global News
- Teletest. Ozempic price in Canada; Wegovy price in Canada (pharmacy prices accessed June 9, 2026). Ozempic · Wegovy
- Ontario Ministry of Health. Ontario Drug Benefit Formulary/Comparative Drug Index, Edition 43: summary of changes, effective June 30, 2026. ontario.ca (PDF)
- Sun Life. Health Canada approves generic GLP-1. Advisor news, 2026. sunlife.ca
- Bloomberg. Aspen Pharmacare wins Canada approval for generic Ozempic after Novo patent expiry. BNN Bloomberg. July 20, 2026. BNN Bloomberg
- Sandoz Canada wins Health Canada approval for generic Ozempic semaglutide (via CNW). September 18, 2026. news report
- Congressional Research Service. Prescription drug importation (IF11056). Updated March 10, 2026. CRS (PDF)
- Gavura S. Generic GLP-1s are coming, but Americans don’t want to wait. Science-Based Medicine. March 12, 2026. sciencebasedmedicine.org
- Health Canada. Drug and health product submissions under review: new drug submissions under review (current as of August 31, 2026). canada.ca
This article summarizes published research and regulatory information for information only and is not medical advice. TrueLabs research compounds are sold for in vitro and laboratory research use only and are not intended for human or veterinary use.